Prostate cancer is the second most common cancer in men in several Indian metro registries, and the National Capital Region carries a particularly heavy share of late-presenting disease[^6]. This page explains how prostate cancer is staged, what each stage means for treatment, and how Indian men and their families can read a pathology or imaging report without getting lost in the vocabulary. The clinical content draws on the NCI Physician Data Query for prostate cancer treatment[^1], the WHO Classification of Urinary and Male Genital Tumours fifth edition[^2], the AJCC and UICC TNM 8 staging manual as adapted by ESMO[^3], the EAU prostate cancer guidelines[^10], and the a tertiary cancer centre Evidence-Based Management protocols for genitourinary cancers[^4]. Burden numbers come from GLOBOCAN 2022[^5] and the ICMR National Centre for Disease Informatics and Research[^6].
What Prostate Cancer Staging Actually Means
Staging in prostate cancer answers three questions at once. How big and how invasive is the tumour inside the gland and beyond it, are the pelvic nodes involved, and is there distant spread to bone, liver, lung, or non-regional nodes. The answers, expressed as a TNM 8 combination and folded into one of four anatomic stages, then meet a second axis the urologist cares about almost as much: the risk group, which combines the PSA, the ISUP Grade Group, and the clinical T category[^1][^4]. A man with a small T1c tumour, PSA 5, and Grade Group 1 sits in a completely different management pathway from a man with the same TNM stage but PSA 28 and Grade Group 4, and the page you are reading exists because that distinction is invisible to most patients walking out of an Indian urology OPD with a one-line report that says “carcinoma prostate”.
Why Prostate Cancer Uses Both TNM and Risk Groups
Most solid tumours are managed off the TNM stage alone. Prostate cancer is the textbook exception, because two men with identical T2cN0M0 disease can have wildly different ten-year outcomes depending on Gleason pattern and PSA. The NCCN, EAU, and a tertiary cancer centre guidelines therefore overlay the D’Amico-style risk groups (very low, low, favourable intermediate, unfavourable intermediate, high, and very high) on top of TNM, and treatment decisions about active surveillance, nerve-sparing radical prostatectomy, dose-escalated radiotherapy, and the duration of androgen deprivation are made on the risk group rather than the stage Roman numeral[^4][^10]. This is why a Phase 1 page that only listed T, N, and M categories would mislead an Indian patient comparing notes with a friend treated at a tertiary cancer centre or a tertiary cancer centre.
Acinar Adenocarcinoma vs Variant Histology
Almost all prostate cancers diagnosed in India are acinar adenocarcinomas arising from the glandular epithelium of the peripheral zone, and the WHO fifth edition keeps this as the default histology[^2]. A smaller share of cases show variant histology that genuinely changes the treatment plan. Ductal adenocarcinoma is more aggressive than acinar disease and tends to give lower PSA values for the same tumour bulk, which means a “reassuring” PSA in a man with a ductal lesion is misleading. Intraductal carcinoma of the prostate, recognised as an adverse feature linked to BRCA2 and other DNA-repair defects, warrants germline testing[^4]. Mucinous and signet-ring variants are uncommon. Small cell or neuroendocrine prostate carcinoma, including treatment-emergent neuroendocrine disease after long androgen blockade, behaves like small cell lung cancer and is treated with platinum-etoposide rather than hormones[^1]. Sarcomatoid carcinoma and prostatic stromal sarcoma are rare and are usually managed at a tertiary cancer centre or a tertiary cancer centre through specialist multidisciplinary boards.
ISUP Grade Groups 1 to 5 and the Gleason Score
The Gleason grading system, now folded into the ISUP and WHO Grade Group 1 to 5 framework, drives both prognosis and treatment intensity, and Indian uropathology departments at a tertiary cancer centre, a tertiary cancer centre, and a tertiary cancer centre report Grade Groups on every biopsy report[^2][^4]. Grade Group 1 (Gleason 3+3=6) behaves indolently and is the group most often offered active surveillance. Grade Group 2 (3+4=7) is favourable intermediate risk, where the dominant pattern is still well-differentiated. Grade Group 3 (4+3=7) is unfavourable intermediate risk because the dominant pattern is now poorly formed glands. Grade Group 4 (4+4, 3+5, or 5+3 = 8) is high risk. Grade Group 5 (Gleason 9 or 10) is very high risk and is usually treated with combined modality therapy from the start. The single most useful question an Indian patient can ask after a biopsy is not “what is my Gleason score” but “what is my Grade Group, and what percentage of cores are involved”.
The T Descriptor: From T1c Biopsy-Detected to T4 Fixed
The T category in TNM 8 for prostate cancer describes how far the primary tumour has grown inside or beyond the gland[^3]. T1 disease is clinically inapparent: T1a and T1b are incidental findings in tissue removed for benign prostatic enlargement (TURP chips), and T1c is the now-dominant category of cancer found only because the PSA was raised and a biopsy was triggered. T2 disease is palpable or visible on imaging but still confined to the prostate, with T2a involving half of one lobe or less, T2b more than half of one lobe, and T2c both lobes. T3 disease has broken through the capsule: T3a is extracapsular extension and T3b is seminal vesicle invasion, both of which are now diagnosed reliably on multiparametric MRI before any surgery is planned. T4 disease is fixed to or invading adjacent structures, classically the bladder neck, external sphincter, rectum, levator muscles, or pelvic wall, and is the category that pushes a patient out of the radical prostatectomy lane and into combined hormone-radiotherapy[^10].
The N Descriptor: Pelvic Lymph Node Involvement
The N descriptor in prostate cancer is binary in TNM 8: N0 means no regional nodal metastasis and N1 means at least one positive node in the true pelvis below the bifurcation of the common iliac arteries[^3]. The regional nodes for prostate cancer are the obturator, internal iliac, external iliac, and presacral groups; everything above the common iliac bifurcation, including the para-aortic chain, counts as M1a non-regional nodal disease, not N1. This boundary matters because a positive obturator node in a man with otherwise high-risk disease is still curable with extended pelvic lymph node dissection plus adjuvant radiotherapy and androgen deprivation in many a tertiary cancer centre and a tertiary cancer centre series, while a positive para-aortic node moves the same patient into the metastatic treatment algorithm with intensified systemic therapy.
The M Descriptor: M1a, M1b, M1c Metastatic Disease
Distant metastases in prostate cancer are split into three sub-categories that have distinct prognostic and treatment implications[^3]. M1a is non-regional lymph node disease above the common iliac bifurcation (para-aortic, retroperitoneal, mediastinal, supraclavicular). M1b is bone metastasis, by far the commonest pattern in Indian tertiary practice, classically osteoblastic lesions in the lumbar spine, pelvis, ribs, and proximal femur. M1c is visceral metastasis to liver, lung, brain, or adrenal, which is uncommon at presentation in adenocarcinoma but typical of treatment-emergent neuroendocrine prostate cancer. The CHAARTED trial established that high-volume metastatic disease (four or more bone metastases with at least one outside the spine and pelvis, or any visceral disease) benefits most from upfront docetaxel added to androgen deprivation, and this volume-based split is still embedded in Indian treatment algorithms[^14].
PSA, Grade Group, T Stage: The Three-Variable Risk Stratification
For localised prostate cancer, the EAU and a tertiary cancer centre guidelines collapse the PSA at diagnosis, the biopsy Grade Group, and the clinical T stage into six risk groups that drive every subsequent treatment decision[^4][^10]. Very low risk requires T1c, Grade Group 1, PSA below 10, fewer than three positive cores, and less than 50 percent involvement of any core. Low risk is T1 to T2a, Grade Group 1, PSA below 10. Favourable intermediate risk is Grade Group 2 with no more than one other intermediate-risk feature. Unfavourable intermediate risk is Grade Group 3 or two-three intermediate-risk features. High risk is T3a, Grade Group 4 or 5, or PSA above 20. Very high risk is T3b-T4, primary Gleason pattern 5, or more than four cores of Grade Group 4-5 disease. An Indian patient asking “is my cancer serious” should be told the risk group, not just the stage.
Stage I Prostate Cancer: Incidental and Low-Volume Disease
Stage I prostate cancer in TNM 8 is T1 or T2a, N0, M0, with PSA below 10 and Grade Group 1[^3]. In an Indian urology clinic this is the man who came in for a corporate health check, had a PSA of 6.4, was sent for an mpMRI that showed a small PI-RADS 4 lesion in the left peripheral zone, and a targeted biopsy that returned 3+3=6 in two of twelve cores. He has a long natural history, and the most appropriate first-line management at a tertiary cancer centre, a tertiary cancer centre, and most NCR private centres is now active surveillance with serial PSA, repeat mpMRI at 12 to 18 months, and confirmatory biopsy, rather than immediate surgery or radiation[^10]. The ProtecT trial showed that for low-risk disease, ten-year prostate-cancer-specific mortality was indistinguishable between surveillance, surgery, and radiotherapy[^22].
Stage II Prostate Cancer: Favourable and Unfavourable Intermediate Risk
Stage II prostate cancer covers T1-T2 disease that does not yet meet stage I criteria because of higher PSA or higher Grade Group, and TNM 8 splits it into IIA, IIB, and IIC based on these features[^3]. Stage IIA is T1-T2a with PSA 10 to 20 or Grade Group 1 with PSA below 20. Stage IIB is T2b-T2c with Grade Group 1, PSA below 20. Stage IIC adds Grade Group 2 or 3. The clinical reality is that most stage II men in NCR practice fall into the favourable or unfavourable intermediate-risk groups, and the choice is between radical prostatectomy with extended pelvic lymph node dissection and dose-escalated external beam radiotherapy with or without four to six months of androgen deprivation[^4]. Active surveillance is sometimes still appropriate for favourable intermediate disease in older men, particularly when life expectancy is below ten years.
Stage III Prostate Cancer: Locally Advanced and High Risk
Stage III prostate cancer in TNM 8 is locally advanced disease, N0, M0, with three sub-stages[^3]. IIIA is T1-T2 with PSA 20 or higher. IIIB is T3-T4 of any PSA, meaning extracapsular extension, seminal vesicle invasion, or fixation to adjacent structures. IIIC is any T with Grade Group 4 or 5, no nodal disease. This is the lane in which combined modality therapy becomes the default: external beam radiotherapy to a dose of 76 to 80 Gy plus 18 to 36 months of androgen deprivation gives the best long-term outcomes in Indian and international series, and surgery (radical prostatectomy with extended pelvic lymph node dissection) is reserved for selected younger men with T3a disease who accept the higher likelihood of needing adjuvant radiotherapy[^4][^10]. The STAMPEDE trial established that adding upfront radiotherapy to androgen deprivation improved survival in men with locally advanced disease[^12].
Stage IV Prostate Cancer: Nodal and Distant Metastases
Stage IV is split into IVA (any T, N1, M0) and IVB (any T, any N, M1), and the two are managed very differently[^3]. Stage IVA, which is regional node-positive non-metastatic disease, is treated as an aggressive locally advanced cancer with curative intent: external beam radiotherapy to the prostate and pelvic nodes plus long-course androgen deprivation, often with the addition of an androgen receptor pathway inhibitor based on the STAMPEDE arm M1RT and arm G data[^12]. Stage IVB is the metastatic state and is treated with systemic therapy from the outset; cure is not the goal, but median survival has more than doubled in the last decade because of the trials covered later on this page. The NCR distinction Indian patients should understand is that “stage 4” in the lay press conflates these two very different scenarios.
Castration-Sensitive vs Castration-Resistant Prostate Cancer
Once a man has metastatic prostate cancer, the most important treatment-shaping label is no longer the TNM stage but whether his disease is still responding to androgen deprivation. Metastatic hormone-sensitive (or castration-sensitive) prostate cancer (mHSPC or mCSPC) is the state in which testosterone suppression below 50 ng/dL still controls PSA and disease. Metastatic castration-resistant prostate cancer (mCRPC) is defined by the Prostate Cancer Working Group 3 as biochemical or radiographic progression on castrate testosterone levels, and is a fundamentally different therapeutic problem[^1]. The transition from mHSPC to mCRPC used to take one to two years on ADT alone; with the upfront intensification strategies established by CHAARTED, LATITUDE, TITAN, ENZAMET, ARASENS, and PEACE-1, the median time on first-line therapy has roughly doubled[^13][^14][^15][^18][^19].
Symptoms of Early Prostate Cancer in Indian Men
Localised prostate cancer (stage I and most stage II) is usually silent[^1]. Many Indian men are picked up because a routine PSA done as part of an executive health check came back above the age-adjusted reference, or because a digital rectal examination during a urology visit for benign prostatic enlargement felt a firm nodule. Lower urinary tract symptoms such as weak stream, hesitancy, nocturia, and a sense of incomplete bladder emptying are far more often caused by benign prostatic hyperplasia than by cancer, but they are the reason a PSA gets ordered in the first place. The clinically important point for the NCR patient is that the absence of urinary symptoms does not mean the absence of prostate cancer: peripheral zone tumours, where most adenocarcinomas arise, sit far enough from the urethra that they cause no obstructive symptoms until they are large.
Symptoms of Locally Advanced and Metastatic Prostate Cancer
As the tumour grows beyond the gland (stage III, locally advanced disease) men may develop haematuria, haematospermia, perineal pain, erectile dysfunction from neurovascular bundle involvement, or obstructive uropathy with rising creatinine when both ureteric orifices are compressed by an enlarging gland or by bulky pelvic nodes[^3]. Locally advanced rectal invasion can cause tenesmus and rectal bleeding. Metastatic prostate cancer (stage IV) most often spreads to bone and pelvic nodes. The classic Indian tertiary clinic presentation is an older man with months of low back or hip pain who finally gets a plain X-ray showing osteoblastic lesions, then a PSA in the hundreds or thousands, then a Tc-99m MDP bone scan or a PSMA PET-CT lighting up the axial skeleton[^4]. Spinal cord compression from a vertebral metastasis is a urological and radiotherapy emergency presenting with progressive leg weakness, saddle anaesthesia, and bladder or bowel dysfunction. Other red flags include unexplained weight loss, anaemia from marrow infiltration, lower limb lymphoedema from bulky pelvic nodes, and pathological fractures.
Risk Factors: Age, Family History, BRCA2 and Lifestyle
Age is the dominant risk factor for prostate cancer. The disease is uncommon before 50, climbs sharply through the 60s and 70s, and the median age at diagnosis in Indian registries sits in the late 60s, slightly older than Western series[^6]. Family history matters: a first-degree relative with prostate cancer roughly doubles the risk, and BRCA2 carriers face a markedly higher lifetime risk and a more aggressive disease course[^1][^4]. Indian families with clusters of breast, ovarian, pancreatic, and prostate cancer should be referred for germline testing through the a tertiary cancer centre or a tertiary cancer centre genetics clinics. Lynch syndrome (mismatch repair deficiency) carries a smaller but real excess risk. Diet and metabolic factors, including obesity and possibly high dairy intake, have been linked to advanced disease in observational cohorts, but no single dietary exposure has been classified as a definite cause by the IARC Monographs working groups[^5]. Vasectomy, benign prostatic hyperplasia, and the frequency of sexual activity are not established causes of prostate cancer despite persistent public belief, and the a tertiary cancer centre guidelines explicitly counsel patients on this point[^4].
PSA Screening: Who, When and How Often in India
India does not have a population-based prostate cancer screening programme, and neither the a tertiary cancer centre nor the a tertiary cancer centre guidelines recommend mass PSA screening, because the harms of overdiagnosis and overtreatment of indolent Grade Group 1 disease outweigh the survival benefit at the population level[^4]. The clinically defensible Indian approach, broadly aligned with the EAU and AUA guidance, is shared decision-making and opportunistic testing in men aged 50 to 70 with a life expectancy of at least ten to fifteen years, started earlier (from 45) in men with a first-degree relative diagnosed with prostate cancer or a known BRCA1/2 carrier[^10][^11]. A baseline PSA in the mid-40s helps stratify subsequent screening intervals: a PSA below 1.0 ng/mL at age 45 to 49 makes future high-grade disease unlikely and supports a five-year retest interval, while a PSA above 1.0 supports annual or biennial testing.
Diagnosis: DRE, mpMRI and Targeted Biopsy
The Indian diagnostic pathway for suspected prostate cancer has changed substantially in the last five years, and the older “raised PSA, straight to twelve-core TRUS biopsy” approach is now obsolete in centres that have multiparametric MRI capacity[^21]. The current EAU and a tertiary cancer centre pathway is: raised age-adjusted PSA or abnormal DRE, repeat PSA to exclude prostatitis or recent instrumentation, then a multiparametric MRI of the prostate (T2, diffusion-weighted, dynamic contrast-enhanced) reported with PI-RADS v2.1[^20]. Men with a PI-RADS 3 or higher lesion proceed to MRI-targeted biopsy, ideally fusion-guided, with concurrent systematic cores from the rest of the gland. Men with a negative MRI and a low PSA density can often safely defer biopsy with surveillance. The PRECISION trial showed that this MRI-first pathway detects more clinically significant cancers and fewer indolent ones than systematic biopsy alone[^21].
PI-RADS Reporting and the Role of mpMRI Before Biopsy
PI-RADS v2.1 is the structured reporting system every Indian patient with a raised PSA should expect to see in their MRI report[^20]. Lesions are scored 1 (very low, clinically significant cancer highly unlikely) through 5 (very high, clinically significant cancer highly likely), based on the dominant sequence in each zone (DWI for peripheral zone, T2 for transition zone). PI-RADS 1 and 2 lesions can usually be managed with PSA surveillance. PI-RADS 3 lesions are equivocal and the decision to biopsy depends on PSA density, age, and family history. PI-RADS 4 and 5 lesions should be biopsied with MRI-targeted cores. The single most useful piece of information an Indian patient can take from an mpMRI report into the urology consultation is the PI-RADS score and the lesion location, because this directly determines whether and how a biopsy is done.
Germline and Somatic Testing: BRCA, HRR and MMR
Molecular testing has become part of the workup for advanced prostate cancer, not just an academic exercise. Homologous recombination repair (HRR) gene defects, especially BRCA2, BRCA1, ATM, PALB2, and CHEK2, define a group eligible for PARP inhibitors such as olaparib, and the PROfound trial established the survival benefit in mCRPC with HRR mutations[^16]. The a tertiary cancer centre and a tertiary cancer centre genetics clinics now offer germline panels for men with metastatic, intraductal, or early-onset prostate cancer or a strong family history of breast, ovarian, pancreatic, or prostate cancer[^4]. Mismatch repair deficiency (Lynch syndrome) is uncommon in prostate cancer but matters because it predicts response to pembrolizumab. Somatic tumour testing on biopsy or metastatic biopsy tissue is the standard for identifying actionable HRR alterations when germline testing is negative.
PSMA PET-CT and Why It Replaced the Bone Scan for High-Risk Disease
The single biggest change in prostate cancer staging in Indian tertiary practice over the last five years has been the routine availability of 68Ga-PSMA PET-CT (and increasingly 18F-PSMA-1007) at major NCR nuclear medicine departments, including a tertiary cancer centre, a tertiary cancer centre, and a leading cancer centre[^4]. PSMA PET-CT is more sensitive and more specific than the combination of Tc-99m MDP bone scan and contrast-enhanced CT abdomen-pelvis for detecting nodal and bone metastases in unfavourable intermediate, high, and very high-risk disease, and the proPSMA trial established this superiority in a randomised setting. The practical implication for an NCR patient with a PSA of 35 and Grade Group 4 disease is that one PSMA PET-CT replaces two older studies, and is substantially more likely to find the small pelvic node or solitary bone lesion that changes management from radical prostatectomy to combined modality therapy.
Treatment of Low-Risk Disease: Active Surveillance
Active surveillance is now the standard of care for very-low-risk and most low-risk prostate cancer in men with a life expectancy of at least ten years, and the EAU, a tertiary cancer centre, and a tertiary cancer centre protocols all endorse it as the preferred first-line option for this group[^4][^10]. The Indian active surveillance schedule typically involves PSA every three to six months for two years then six-monthly, mpMRI at 12 to 18 months, and a confirmatory biopsy at one year (or earlier if PSA kinetics or MRI change). Triggers to switch to definitive treatment include a rise in Grade Group on repeat biopsy, a substantial increase in tumour volume on imaging, or a clear PSA doubling. The ProtecT trial confirmed that prostate-cancer-specific mortality at ten years for low-risk disease managed by surveillance was equivalent to surgery or radiotherapy, although metastasis rates were slightly higher in the surveillance arm[^22].
Treatment of Intermediate-Risk Disease: Surgery vs Radiotherapy
Intermediate-risk prostate cancer (stage IIB-IIC, favourable and unfavourable) is the lane in which the choice between radical prostatectomy and external beam radiotherapy is most contested, and Indian centres tend to favour the modality each centre is strongest in[^4]. Robot-assisted radical prostatectomy with extended pelvic lymph node dissection (for unfavourable intermediate disease) is the dominant surgical approach at leading cancer centres in the region, and a leading cancer centre NCR centres, with shorter hospital stays and faster recovery than open retropubic surgery. Dose-escalated external beam radiotherapy (76 to 80 Gy in 38 to 40 fractions, or moderately hypofractionated 60 Gy in 20 fractions) plus four to six months of androgen deprivation for unfavourable intermediate disease is the dominant radiotherapy approach, increasingly delivered as IMRT or VMAT[^10]. Brachytherapy boost is offered at selected NCR centres for favourable disease with small gland volumes.
Treatment of High-Risk and Locally Advanced Disease
High-risk and very-high-risk localised prostate cancer (stage III, IIIA-IIIC) is the group in which combined modality therapy gives the best long-term outcomes, and the STAMPEDE trial settled the question of whether radiotherapy added to androgen deprivation improved survival: it does, especially for node-positive and locally advanced disease[^12]. The current a tertiary cancer centre and a tertiary cancer centre protocol for high-risk disease is external beam radiotherapy to the prostate and seminal vesicles (with or without pelvic node coverage based on the Roach formula or PSMA PET findings) to 78 Gy or equivalent hypofractionated dose, plus 18 to 36 months of androgen deprivation, often combined with an androgen receptor pathway inhibitor (abiraterone or enzalutamide) based on the STAMPEDE arm G data[^12]. Radical prostatectomy is offered to selected younger men with T3a disease, with the understanding that adjuvant or early salvage radiotherapy will likely be required for positive margins or rising PSA.
Treatment of Metastatic Castration-Sensitive Prostate Cancer
Metastatic castration-sensitive prostate cancer (mCSPC) is no longer treated with androgen deprivation alone. Six pivotal trials have established that upfront intensification with either docetaxel or an androgen receptor pathway inhibitor (or both) substantially improves overall survival[^13][^14][^15][^18][^19]. CHAARTED and STAMPEDE-docetaxel established the survival benefit of adding six cycles of docetaxel to ADT, particularly in high-volume disease[^12][^14]. LATITUDE and STAMPEDE-abiraterone established the benefit of adding abiraterone plus prednisolone[^13]. TITAN and ENZAMET established the benefit of adding apalutamide and enzalutamide respectively[^15]. ARASENS established the triplet of ADT plus docetaxel plus darolutamide as the new standard for high-volume mCSPC[^18]. PEACE-1 established the triplet of ADT plus docetaxel plus abiraterone, and also the role of upfront prostate radiotherapy in low-volume disease[^19]. The Indian cost-effectiveness reality means apalutamide and abiraterone (now widely available as generics) are the workhorses, with darolutamide reserved for selected patients.
Treatment of Castration-Resistant Disease: ARPI, Chemo, PARP, Lutetium
Once a man progresses to metastatic castration-resistant prostate cancer (mCRPC), treatment sequencing depends on what he received in the castration-sensitive setting and on his molecular profile[^1]. The available active agents in Indian practice are: abiraterone plus prednisolone, enzalutamide, docetaxel, cabazitaxel (post-docetaxel), olaparib (for BRCA2 and other HRR mutations, based on PROfound)[^16], rucaparib, 177Lu-PSMA-617 (for PSMA-positive mCRPC after ARPI and taxane, based on the VISION trial)[^17], radium-223 (for symptomatic bone-only mCRPC), and pembrolizumab for the rare MMR-deficient or high TMB tumour. Lutetium-177 PSMA therapy is now offered at leading cancer centres in the region, and a small number of other NCR nuclear medicine departments, with each cycle costing in the range of two to three lakh rupees out of pocket. Sequencing decisions should be made by a multidisciplinary tumour board.
Cost of Prostate Cancer Treatment in Delhi, Gurgaon and Noida
Out-of-pocket costs for prostate cancer treatment in the NCR vary widely between a tertiary cancer centre (heavily subsidised), other government centres (leading cancer centres), and private hospitals (leading cancer centres). As of early 2026, indicative private-sector ranges are: robot-assisted radical prostatectomy with extended pelvic lymph node dissection 3.5 to 6 lakh rupees, dose-escalated IMRT to the prostate and pelvis 2.5 to 5 lakh, brachytherapy boost 1 to 2 lakh, six cycles of docetaxel chemotherapy 60,000 to 1.2 lakh, abiraterone plus prednisolone (now widely available as Indian generic) 4,000 to 12,000 per month, enzalutamide and apalutamide 25,000 to 60,000 per month, olaparib 80,000 to 1.5 lakh per month, and 177Lu-PSMA-617 therapy 2 to 3 lakh per cycle for typically four to six cycles. These figures should be treated as orientation only; every patient needs a written estimate from the specific centre and confirmation of insurance and Ayushman Bharat coverage where applicable[^9].
Frequently Asked Questions About Prostate Cancer Stages
Is a PSA of 6 a sign of prostate cancer? Not on its own. A PSA of 6 in a 65-year-old Indian man is mildly raised and is far more likely to reflect benign prostatic enlargement, prostatitis, or recent instrumentation than cancer. The next step is repeat PSA after a few weeks, a digital rectal examination, and, if still raised, a multiparametric MRI of the prostate before any biopsy[^21].
What is the difference between Gleason score and Grade Group? The Gleason score adds the two most common patterns in the biopsy (for example 3+4=7). Grade Groups 1 to 5 simplify this for patients and clinicians: Grade Group 1 is Gleason 6, Grade Group 2 is 3+4, Grade Group 3 is 4+3, Grade Group 4 is Gleason 8, and Grade Group 5 is Gleason 9 to 10[^2].
Is stage 4 prostate cancer always terminal? No. Stage IVA (regional node-positive, no distant metastasis) is treated with curative intent in many cases. Stage IVB (distant metastasis) is not currently curable, but median survival has more than doubled in the last decade with upfront intensification using abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, olaparib, and 177Lu-PSMA-617[^14][^17][^18].
Should I get a PSA test if my father had prostate cancer? Yes. A first-degree relative with prostate cancer roughly doubles your risk, and the EAU and AUA guidelines recommend starting shared-decision PSA testing five years earlier than the general population, typically from age 45[^10][^11]. If the relative was a BRCA1 or BRCA2 carrier, germline testing should be discussed.
How often do Indian men with low-risk prostate cancer on active surveillance progress? In published a tertiary cancer centre and a tertiary cancer centre series, roughly one in three men on active surveillance for very-low or low-risk disease will eventually require definitive treatment within five to seven years, most often because of an upgrade in Grade Group on repeat biopsy rather than because of metastatic progression[^4].
Sources:
[^1] National Cancer Institute. Prostate Cancer Treatment (PDQ) Health Professional Version. https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
[^2] WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th ed., Vol 8. IARC, 2022.
[^3] Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 2020. https://www.esmo.org/guidelines/genitourinary-cancers/prostate-cancer
[^4] a tertiary cancer centre. Evidence Based Management of Cancers in India: Genitourinary Cancers. https://a tertiary cancer centre.gov.in/index.php/en/ebm-guidelines
[^5] IARC. GLOBOCAN 2022: India fact sheet. https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
[^6] ICMR-NCDIR. National Cancer Registry Programme Report 2020. https://ncdirindia.org/All_Reports/Report_2020/
[^7] WHO. Cancer Country Profile: India 2020.
[^8] NCI SEER. Cancer Stat Facts: Prostate Cancer. https://seer.cancer.gov/statfacts/html/prost.html
[^9] a tertiary cancer centre Department of Urology. Clinical practice protocols for prostate cancer.
[^10] EAU Guidelines on Prostate Cancer. https://uroweb.org/guidelines/prostate-cancer
[^11] AUA/ASTRO/SUO Guideline on Localized Prostate Cancer (2022).
[^12] STAMPEDE trial. James ND et al. Lancet 2016, 2017, 2022.
[^13] LATITUDE trial. Fizazi K et al. NEJM 2017.
[^14] CHAARTED trial. Sweeney CJ et al. NEJM 2015.
[^15] TITAN trial (apalutamide). Chi KN et al. NEJM 2019. ENZAMET (enzalutamide). Davis ID et al. NEJM 2019.
[^16] PROfound trial (olaparib). de Bono J et al. NEJM 2020.
[^17] VISION trial (177Lu-PSMA-617). Sartor O et al. NEJM 2021.
[^18] ARASENS trial (darolutamide). Smith MR et al. NEJM 2022.
[^19] PEACE-1 trial. Fizazi K et al. Lancet 2022.
[^20] PI-RADS v2.1. Turkbey B et al. European Urology 2019.
[^21] PRECISION trial (mpMRI before biopsy). Kasivisvanathan V et al. NEJM 2018.
[^22] ProtecT trial. Hamdy FC et al. NEJM 2016, 2023.
Overview
Treatment Options